Jie Lian

Title: Innovations of Jie Lian in Diabetes Treatment

Introduction

Jie Lian is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that can aid in the treatment of type II diabetes. His innovative work has the potential to impact the lives of many individuals suffering from this condition.

Latest Patents

Jie Lian holds a patent for Thienyl [3,2-D] pyrimidin-4-one compounds. This patent includes a preparation method, pharmaceutical compositions, and their use. The disclosed compounds are strong DPPIV (dipeptide peptidase IV) inhibitors. They can treat type II diabetes by indirectly increasing the content of GLP-1 in vivo, which induces a series of physiological actions beneficial for patients. This innovation positions the compounds as promising new drugs for diabetes treatment.

Career Highlights

Throughout his career, Jie Lian has worked with esteemed organizations such as the Chinese Academy of Sciences and Cisen Pharmaceutical Co., Ltd. His experience in these institutions has allowed him to refine his research and contribute to significant advancements in pharmaceutical sciences.

Collaborations

Jie Lian has collaborated with notable colleagues, including Hong Tao Liu and Jia Tao Li. Their combined expertise has fostered an environment of innovation and discovery in their respective fields.

Conclusion

Jie Lian's contributions to diabetes treatment through his patented compounds highlight his role as an influential inventor in the pharmaceutical industry. His work not only showcases his innovative spirit but also offers hope for improved treatment options for those affected by diabetes.